Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

12 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Injured nerves may cause severe pain in patients with sickle cell disease

Researchers at the University of Illinois at Chicago have discovered the pain caused by sickle cell disease may not occur solely from damaged tissues, but also from injured nerves.

11 Mar 2010

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.

10 Mar 2010

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Allergan, Inc. today announced that the United States Food and Drug Administration has approved BOTOX® (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.

9 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

Abused children more likely to suffer abdominal pain and nausea

Children who have been abused psychologically, physically or sexually are more likely to suffer unexplained abdominal pain and nausea or vomiting than children who have not been abused, a study led by University of North Carolina at Chapel Hill researchers concludes.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Electromagnetic pulses significantly decrease pain and inflammation associated with osteoarthritis of the knee, according to Henry Ford Hospital researchers.

7 Mar 2010

Salmonella Montevideo outbreak: FDA investigates Daniele International's pepper supply chain

As part of the Salmonella Montevideo investigation, the Food and Drug Administration has been actively investigating the supply chain of black and red pepper supplied to Daniele International Inc., Pascoag, R.I.

6 Mar 2010

Salmonella Tennessee in Basic Food Flavors' HVP: FDA taking steps to protect consumers

The U.S. Food and Drug Administration is taking steps to protect the public following the early identification of Salmonella Tennessee in one company's supply of hydrolyzed vegetable protein (HVP). This is a common ingredient used most frequently as a flavor enhancer in many processed foods, including soups, sauces, chilis, stews, hot dogs, gravies, seasoned snack foods, dips and dressings.

6 Mar 2010

Possible Salmonella contamination: Mincing Overseas Spice recalls two lots of black pepper

Mincing Overseas Spice Company of Dayton, New Jersey announced today that it is recalling black pepper Lots 3258 and 3309 because of possible contamination with Salmonella.

6 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Inpatient integrative medicine program can have significant impact on pain: Study

Non-traditional therapies relieve pain among a wide range of hospitalized patients as much as 50 percent, according to a first-of-a-kind study in the Journal of Patient Safety.

6 Mar 2010

FDA takes steps to protect consumers from potential Salmonella infection

5 Mar 2010

Nausea News and Research

Further Reading

New MMMCC center improves patients’ access to medical marijuana

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Injured nerves may cause severe pain in patients with sickle cell disease

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Abused children more likely to suffer abdominal pain and nausea

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Salmonella Montevideo outbreak: FDA investigates Daniele International's pepper supply chain

Salmonella Tennessee in Basic Food Flavors' HVP: FDA taking steps to protect consumers

Possible Salmonella contamination: Mincing Overseas Spice recalls two lots of black pepper

Presentation of results from open-label extension study of Xenazine

Inpatient integrative medicine program can have significant impact on pain: Study

FDA takes steps to protect consumers from potential Salmonella infection

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News